(NKTR) Nektar Therapeutics BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(NKTR) Nektar Therapeutics Complete Analysis Pack
See the Bigger Picture
This Nektar Therapeutics BCG Matrix helps you see how the company’s products or business units may be positioned across Stars, Cash Cows, Question Marks, and Dogs for strategy and capital-allocation decisions. The content shown on this page is a real preview of the actual analysis, not just a teaser, so you can review the format before buying. Purchase the full version to get the complete ready-to-use report.
Stars
0 marketed products
Nektar Therapeutics had 0 marketed products by end-2025, so it had no true BCG Star with an established market share. The company still had no approved commercial drug, so growth depended on pipeline execution, not on a sales leader. In 2025, that left its value case tied to clinical progress and partnering, not to product revenue.
NKTR-255 Phase 1/2
NKTR-255 Phase 1/2 is Nektar Therapeutics’ clearest near-term growth driver, with ongoing studies in non-Hodgkin’s lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. If updated clinical readouts show stronger response and durability, this asset could move from pipeline promise to a true Star and support higher future value.
NKTR-358 Phase 2
NKTR-358 is a Phase 2 Stars asset for Nektar Therapeutics, aimed at immune-mediated disease with active studies in systemic lupus erythematosus and ulcerative colitis. It also has Phase 1B work in atopic dermatitis and psoriasis, broadening its reach across high-need inflammation markets. If efficacy and safety hold up, it could move from a niche pipeline bet to a high-value lead program.
NKTR-262 Phase 1/2
NKTR-262 is still an early Phase 1/2 solid-tumor program, so its current market share is effectively 0 and it has not yet shown commercial scale. In a large oncology market, it only fits the Stars bucket if later data prove safety, response, and a clear path to registration.
For now, it is a high-upside option, not a proven driver of Nektar Therapeutics value.
- Phase 1/2 only
- Solid-tumor focus
- Current share: 0
- Star only after success
Late-stage oncology and immunology pipeline
Nektar Therapeutics’ most valuable oncology and immunology assets are still clinical-stage, so the portfolio is not yet earning Star status. That means the company is still in an investment phase, with R&D spend and trial execution driving value more than sales. The shift to a true Star only starts after approval and market adoption.
- Clinical assets, not commercial products, drive value.
- High R&D keeps cash needs elevated.
- Approval and uptake are the Star trigger.
Nektar’s “Stars” Were Still Clinical, Not Commercial
Nektar Therapeutics had no marketed products by end-2025, so it had no true Stars in the BCG sense. NKTR-255 and NKTR-358 were its best Star-like clinical assets, but both were still precommercial, with value tied to Phase 1/2 and Phase 2 data, not sales.
| Asset | Stage | Star status |
|---|---|---|
| NKTR-255 | Phase 1/2 | Potential |
| NKTR-358 | Phase 2 | Potential |
What is included in the product
Detailed Word Document
Nektar Therapeutics BCG Matrix: one-line view of pipeline units to invest in, hold, or divest.
Editable Excel File
One-page Nektar Therapeutics BCG Matrix to spot pain points and quadrant priorities fast
Reference Sources
Provides a clear source trail for Nektar Therapeutics data, strengthening credibility and speeding due diligence.
Cash Cows
0 approved drugs
Nektar Therapeutics had 0 approved drugs at end-2025, so it had no true Cash Cow under BCG rules. With no commercialized product base, it did not have a mature brand or a stable operating cash stream to fund other units. That left 2025 revenue pressure on its pipeline and partnerships, not on recurring product sales.
0 mature franchises
Nektar Therapeutics had 0 mature franchises, so it lacked the classic Cash Cow profile: a low-growth business with high share and steady cash. In FY2025, cash generation still depended on collaboration income and outside financing, not on a durable product engine. That left the BCG slot empty and kept operating cash flow volatile.
Collaboration-driven funding
Nektar Therapeutics’ collaboration-driven funding is a cash cow because it kept agreements with 10 partners, including Takeda, AstraZeneca, UCB, Roche, Bausch Health, Pfizer, Amgen, Bristol Myers Squibb, Eli Lilly, Merck KGaA, and SFJ Pharmaceuticals. These deals can still bring milestone payments and partner-funded R&D, which helps cash flow. But this is not the same as a self-funding product franchise, so the income can be uneven.
R&D-heavy cost base
Nektar Therapeutics stayed research-intensive in 2025, so cash was still going into trials and development instead of being harvested from steady sales. That is the opposite of a Cash Cow profile: the business was funding pipeline work, not milking mature products for cash.
- R&D spend stayed the main cash use.
- Sales did not cover development burn.
- Profile fits Question Mark, not Cash Cow.
No royalty engine
Nektar Therapeutics had no large royalty stream from a marketed asset, so it lacked the low-growth, high-margin cash engine that defines a Cash Cow. That kept cash flow tied to pipeline wins, with revenue still small and volatile versus a royalty-led model.
- No marketed-asset royalty base.
- Cash flow stayed pipeline-dependent.
- No stable high-margin annuity.
Nektar: No Cash Cow in FY2025—Just a Question Mark
Nektar Therapeutics had no Cash Cow in FY2025. With 0 approved drugs and no marketed royalty base, cash stayed tied to collaboration income and R&D burn, not a mature, self-funding product line. That makes its BCG profile Question Mark, not Cash Cow.
| Metric | FY2025 |
|---|---|
| Approved drugs | 0 |
| Commercial cash cow | None |
| Partner collaborations | 10 |
Preview the Actual Deliverable
Nektar Therapeutics Reference Sources
The Nektar Therapeutics BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No sample pages, no watermarks—just the complete, professionally formatted report. Once purchased, your file is instantly available for download and use. What you preview is exactly what you get.
Dogs
Bempegaldesleukin Phase 3 metastatic melanoma
Bempegaldesleukin was a late-stage metastatic melanoma bet in a crowded checkpoint-inhibitor market, so its BCG fit slipped toward Dog as odds worsened. Nektar Therapeutics reported the Phase 3 PIVOT IO-001 study missed its primary endpoint in 2023, with no proven commercial edge against dominant PD-1 regimens. That made the program a capital drain rather than a growth engine.
Bempegaldesleukin Phase 3 renal cell carcinoma
The RCC program was a high-cost, late-stage bet, but Nektar Therapeutics said on Nov. 16, 2021 that bempegaldesleukin failed its Phase 3 PIVOT-09 endpoint in clear cell renal cell carcinoma. With no clear efficacy edge over standard immuno-oncology care, it sat in Dog territory: heavy spend, weak share, poor return.
Bempegaldesleukin Phase 3 muscle-invasive bladder cancer
Bempegaldesleukin in Phase 3 muscle-invasive bladder cancer fits a Dog: Nektar had already sunk heavy R&D into a hard-to-win setting, but the path to sales was weak without clear superiority over standard regimens. When a program cannot turn trial spend into durable market value, it destroys cash instead of creating it.
Bempegaldesleukin Phase 3 head and neck squamous cell carcinoma
Bempegaldesleukin in phase 3 head and neck squamous cell carcinoma sits in a crowded PD-1 driven market. Nektar Therapeutics' PIVOT IO-001 program did not show a clear efficacy edge, so the asset has stayed a Dog: low share, low growth, and no approval momentum.
- Phase 3 failed to win clear benefit.
- Competitive risk stayed high.
- Market share likely remains negligible.
- BCG fit: Dog.
Bempegaldesleukin Phase 1B COVID-19
Bempegaldesleukin’s Phase 1b COVID-19 work fits the Dog box: by 2025, COVID-19 was no longer a high-growth market, and a small exploratory study has little stand-alone value. Nektar Therapeutics has not disclosed meaningful COVID-specific revenue from this program, so the commercial share is effectively minimal. With late-stage pandemic demand fading, the asset is more a legacy research item than a growth driver.
- Low growth by end-2025
- Small study, limited upside
- Negligible revenue impact
- Classic Dog in BCG terms
Bempegaldesleukin: Nektar's Lost Growth Bet
Bempegaldesleukin is a Dog for Nektar Therapeutics because it lost its main growth case: Phase 3 PIVOT IO-001 missed its endpoint in 2023, and PIVOT-09 failed on Nov. 16, 2021. In a crowded PD-1 market, that left low share, weak pricing power, and no clear path to revenue.
| Asset | Key data | BCG fit |
|---|---|---|
| Bempegaldesleukin | PIVOT IO-001 miss; PIVOT-09 miss | Dog |
Question Marks
NKTR-358 Phase 2 systemic lupus erythematosus
NKTR-358 is a pure Question Mark: Nektar Therapeutics has no commercial share in systemic lupus erythematosus, but the market is still expanding, with global SLE therapy demand expected to stay in the multi-billion-dollar range through 2026. If Phase 2 data show clear disease control and tolerability, the asset could move from optionality to value driver. Until then, it stays high risk and unproven.
NKTR-358 Phase 2 ulcerative colitis
Ulcerative colitis is a large, active market, with millions of patients worldwide and steady R&D spending across biologics and JAKs. NKTR-358 is still unproven in both clinic and market, so it sits as a Question Mark in Nektar Therapeutics’ BCG matrix. It needs clear Phase 2 efficacy and safety data before heavy capital gets harder to justify.
NKTR-358 Phase 1B atopic dermatitis and psoriasis
NKTR-358’s Phase 1b readout in atopic dermatitis and psoriasis sits in two large markets: atopic dermatitis affects about 16.5 million U.S. adults, and psoriasis about 7.5 million. But Phase 1b data are still too early to prove durable efficacy or win share against entrenched biologics and JAKs. That keeps NKTR-358 in the high-potential, high-uncertainty bucket.
NKTR-255 Phase 1/2 hematologic cancers
NKTR-255 has shots in lymphoma and multiple myeloma, two high-value oncology markets, but Nektar Therapeutics still has no marketed position. The asset stays a Question Mark until Phase 1/2 data show durable responses, clean safety, and stronger proof in these hematologic cancers.
Big market, no revenue yet.
Needs deeper, lasting data.
Star status depends on maturation.
NKTR-262 Phase 1/2 solid tumors
NKTR-262 in phase 1/2 for solid tumors fits the Question Mark box: the solid-tumor market is huge, but this asset still has low share and no approved sales. In 2025/2026, it remains an early clinical bet with high readout and development risk, so value is still optionality, not earnings.
- Huge TAM, but no commercial share
- Early phase, high clinical risk
- Value depends on 2026 data
Nektar’s Early-Stage Pipeline Holds High-Upside But Needs Proof
Nektar Therapeutics’ Question Marks are early, high-upside assets with no commercial share yet. NKTR-358, NKTR-255, and NKTR-262 all target large 2025/2026 markets, but each still needs stronger Phase 1/2 or Phase 2 proof before value can shift from optionality to revenue.
| Asset | 2025/2026 status | Why Question Mark |
|---|---|---|
| NKTR-358 | Early clinic | No sales; SLE, UC, AD, psoriasis upside |
| NKTR-255 | Early clinic | Lymphoma, myeloma; no market share |
| NKTR-262 | Phase 1/2 | Solid tumors; high risk, no revenue |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.